TUESDAY, June 25, 2024 -- A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows.
Fenofibrate (Tricor) has been approved since 2004 as a means of lowering cholesterol. Now, this new study shows that fenofibrate also can reduce the progression of diabetic retinopathy by 27% compared to placebo.
The findings were published June 21 in the journal NEJM Evidence and presented simultaneously at the American Diabetes Association’s annual meeting in Orlando, Fla.
The results from the new trial “suggest that fenofibrate may provide a valuable addition to treat people with diabetic retinopathy,” Preiss added in a meeting news release.
Diabetic retinopathy occurs when elevated blood sugar levels damage blood vessels in the back of the eye. The vessels start to swell and leak, eventually leading to blurry vision, blank spots and blindness.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.